Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06715683 | A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants | PHASE1 | COMPLETED | 48 | — | — | Dec 12, 2024 | Mar 16, 2025 | Apr 4, 2025 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Part 1, Sequence 1 | EXPERIMENTAL | - |
| Part 1, Sequence 2 | EXPERIMENTAL | - |
| Part 2, Sequence 1 | EXPERIMENTAL | - |
| Part 2, Sequence 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986278 Batched method, Dose A | DRUG | Specified dose on specified days |
| BMS-986278 Batched method, Dose B | DRUG | Specified dose on specified days |
| BMS-986278 Continuous method | DRUG | Specified dose on specified days |
Inclusion Criteria: * Healthy female individuals not of childbearing potential (INOCBP) and males, healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory assessment results as determined by the investigator. * Body mass ...